Advertisement
Erratum Free access | 10.1172/JCI63915
Find articles by Kishore, P. in: JCI | PubMed | Google Scholar
Find articles by Boucai, L. in: JCI | PubMed | Google Scholar
Find articles by Zhang, K. in: JCI | PubMed | Google Scholar
Find articles by Li, W. in: JCI | PubMed | Google Scholar
Find articles by Koppaka, S. in: JCI | PubMed | Google Scholar
Find articles by Kehlenbrink, S. in: JCI | PubMed | Google Scholar
Find articles by Schiwek, A. in: JCI | PubMed | Google Scholar
Find articles by Esterson, Y. in: JCI | PubMed | Google Scholar
Find articles by Mehta, D. in: JCI | PubMed | Google Scholar
Find articles by Bursheh, S. in: JCI | PubMed | Google Scholar
Find articles by Su, Y. in: JCI | PubMed | Google Scholar
Find articles by Gutierrez-Juarez, R. in: JCI | PubMed | Google Scholar
Find articles by Muzumdar, R. in: JCI | PubMed | Google Scholar
Find articles by Schwartz, G. in: JCI | PubMed | Google Scholar
Find articles by Hawkins, M. in: JCI | PubMed | Google Scholar
Published June 1, 2012 - More info
Increased endogenous glucose production (EGP) is a hallmark of type 2 diabetes mellitus. While there is evidence for central regulation of EGP by activation of hypothalamic ATP-sensitive potassium (KATP) channels in rodents, whether these central pathways contribute to regulation of EGP in humans remains to be determined. Here we present evidence for central nervous system regulation of EGP in humans that is consistent with complementary rodent studies. Oral administration of the KATP channel activator diazoxide under fixed hormonal conditions substantially decreased EGP in nondiabetic humans and Sprague Dawley rats. In rats, comparable doses of oral diazoxide attained appreciable concentrations in the cerebrospinal fluid, and the effects of oral diazoxide were abolished by i.c.v. administration of the KATP channel blocker glibenclamide. These results suggest that activation of hypothalamic KATP channels may be an important regulator of EGP in humans and that this pathway could be a target for treatment of hyperglycemia in type 2 diabetes mellitus.
Preeti Kishore, Laura Boucai, Kehao Zhang, Weijie Li, Sudha Koppaka, Sylvia Kehlenbrink, Anna Schiwek, Yonah B. Esterson, Deeksha Mehta, Samar Bursheh, Ya Su, Roger Gutierrez-Juarez, Radhika Muzumdar, Gary J. Schwartz, Meredith Hawkins
Original citation: J. Clin. Invest. 2011;121(12): 4916–4920. doi:10.1172/JCI58035.
Citation for this erratum: J. Clin. Invest. 2012;122(6):2326. doi:10.1172/JCI63915.
The JCI regrets that, during the preparation of this manuscript, the data for Figure 3, C and D, were inadvertently duplicated in panels A and B. The correct figure is below.